Edgewise Therapeutics Statistics
Total Valuation
EWTX has a market cap or net worth of $3.06 billion. The enterprise value is $2.54 billion.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
| Earnings Date | Nov 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
EWTX has 94.69 million shares outstanding. The number of shares has increased by 34.04% in one year.
| Current Share Class | 94.69M |
| Shares Outstanding | 94.69M |
| Shares Change (YoY) | +34.04% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 0.55% |
| Owned by Institutions (%) | 70.45% |
| Float | 58.85M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 6.17 |
| P/TBV Ratio | 6.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.35, with a Debt / Equity ratio of 0.01.
| Current Ratio | 26.35 |
| Quick Ratio | 25.98 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -31.90% and return on invested capital (ROIC) is -23.31%.
| Return on Equity (ROE) | -31.90% |
| Return on Assets (ROA) | -22.36% |
| Return on Capital (ROIC) | -23.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.41M |
| Employee Count | 88 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +403.97% in the last 52 weeks. The beta is 0.15, so EWTX's price volatility has been lower than the market average.
| Beta (5Y) | 0.15 |
| 52-Week Price Change | +403.97% |
| 50-Day Moving Average | 30.66 |
| 200-Day Moving Average | 21.12 |
| Relative Strength Index (RSI) | 48.88 |
| Average Volume (20 Days) | 679,472 |
Short Selling Information
The latest short interest is 7.29 million, so 7.70% of the outstanding shares have been sold short.
| Short Interest | 7.29M |
| Short Previous Month | 8.49M |
| Short % of Shares Out | 7.70% |
| Short % of Float | 12.39% |
| Short Ratio (days to cover) | 7.56 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -147.15M |
| Pretax Income | -115.88M |
| Net Income | -124.29M |
| EBITDA | -145.18M |
| EBIT | -147.15M |
| Earnings Per Share (EPS) | -$1.46 |
Full Income StatementBalance Sheet
The company has $492.54 million in cash and $4.44 million in debt, giving a net cash position of $488.10 million or $5.15 per share.
| Cash & Cash Equivalents | 492.54M |
| Total Debt | 4.44M |
| Net Cash | 488.10M |
| Net Cash Per Share | $5.15 |
| Equity (Book Value) | 488.88M |
| Book Value Per Share | 5.18 |
| Working Capital | 480.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$108.90 million and capital expenditures -$1.20 million, giving a free cash flow of -$110.10 million.
| Operating Cash Flow | -108.90M |
| Capital Expenditures | -1.20M |
| Free Cash Flow | -110.10M |
| FCF Per Share | -$1.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |